Daljeet Kohli’s experience with Ajanta Pharma and Shilpa Medicare shows that it is not enough to identify winning stocks. To reap the full benefit, we must have the sagacity to remain invested inspite of temporary periods of over-valuation and adversities
When we come across a seriously attractive investment opportunity, we must not get into a decision making paralysis. Instead, we must buy first and think later says Rakesh Jhunjhunwala
Rakesh Jhunjhunwala says we should avoid much fancied stocks quoting at high valuations and instead focus on stocks whose valuations are attractive. This strategy could lead to under-performance in the short-term but will pay off well in the long run, he says
Shilpa Medicare’s spectacular jump of 17% today is not an isolated instance. Most of the stocks hand-picked by Raamdeo Agrawal as potential multi-baggers are sparkling
Recent Comments